Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2024,
Zai Lab paidHK$0 Mil more to buy back shares than it received from issuing new shares.
It receivedHK$377 Mil from issuing more debt.
It paidHK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedHK$0 Mil from paying cash dividends to shareholders.
It spentHK$5 Mil on other financial activities.
In all, Zai LabearnedHK$372 Mil on financial activities for the
three
months ended in Mar. 2024.
Zai Lab Cash Flow from Financing Historical Data
The historical data trend for Zai Lab's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Zai Lab's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$352 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (HKSE:09688) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Zai Lab's issuance of stock for the
three
months ended in Mar. 2024 was HK$0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Zai Lab's repurchase of stock for the
three
months ended in Mar. 2024 was HK$0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Zai Lab's net issuance of debt for the
three
months ended in Mar. 2024 was HK$377 Mil.
Zai Lab receivedHK$377 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Zai Lab's net issuance of preferred for the
three
months ended in Mar. 2024 was HK$0 Mil.
Zai Lab paidHK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Zai Lab's cash flow for dividends for the
three
months ended in Mar. 2024 was HK$0 Mil.
Zai Lab receivedHK$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Zai Lab's other financing for the
three
months ended in Mar. 2024 was HK$-5 Mil.
Zai Lab spentHK$5 Mil on other financial activities.
Zai Lab Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Zai Lab's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09688 has been successfully added to your 